| 11 11 (0%) | 12-17 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 12.84 | 1-year : | 15 |
| Resists | First : | 11 | Second : | 12.84 |
| Pivot price | 10.93  |
|||
| Supports | First : | 10.78 | Second : | 10.65 |
| MAs | MA(5) : | 10.97 |
MA(20) : | 10.88 |
| MA(100) : | 6.82 |
MA(250) : | 0 | |
| MACD | MACD : | 0.5 |
Signal : | 0.7 |
| %K %D | K(14,3) : | 97.9 |
D(3) : | 97.2 |
| RSI | RSI(14): 84.5 | |||
| 52-week | High : | 11 | Low : | 1.94 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ EVOK ] has closed below upper band by 10.8%. Bollinger Bands are 92.7% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 16 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 11.02 - 11.07 | 11.07 - 11.12 |
| Low: | 10.87 - 10.93 | 10.93 - 10.98 |
| Close: | 10.91 - 11.01 | 11.01 - 11.08 |
Evoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It is developing Gimoti, a metoclopramide nasal spray that has completed Phase 3 clinical trials to treat symptoms associated with acute and recurrent diabetic gastroparesis in females. The company markets its products to gastroenterologists, internal medicine specialists, primary care physicians, and select health care providers. Evoke Pharma, Inc. was incorporated in 2007 and is headquartered in Solana Beach, California.
Thu, 18 Dec 2025
Evoke Pharma and QOL Medical Announce Expiration of Tender Offer - BioSpace
Wed, 17 Dec 2025
Evoke Pharma investors get $11 a share as the company leaves Nasdaq - Stock Titan
Wed, 17 Dec 2025
Evoke Pharma acquired by QOL Medical, shares to be delisted from Nasdaq - Investing.com
Tue, 04 Nov 2025
Evoke Pharma (EVOK) Soars Over 130% on Acquisition News - GuruFocus
Tue, 04 Nov 2025
EVOK Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Evoke Pharma, Inc. is Fair to Shareholders - Business Wire
Tue, 04 Nov 2025
Evoke Pharma Enters into Definitive Agreement to Be Acquired by QOL Medical - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | 2 (M) |
| Shares Float | 1 (M) |
| Held by Insiders | 10.6 (%) |
| Held by Institutions | 25 (%) |
| Shares Short | 7 (K) |
| Shares Short P.Month | 8 (K) |
| EPS | -1.38 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.55 |
| Profit Margin | -36.3 % |
| Operating Margin | -26.6 % |
| Return on Assets (ttm) | -21.8 % |
| Return on Equity (ttm) | -134.9 % |
| Qtrly Rev. Growth | 61.4 % |
| Gross Profit (p.s.) | 8.13 |
| Sales Per Share | 8.38 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -3 (M) |
| Levered Free Cash Flow | -2 (M) |
| PE Ratio | -7.98 |
| PEG Ratio | 0 |
| Price to Book value | 7.05 |
| Price to Sales | 1.31 |
| Price to Cash Flow | -5.7 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|